• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 19, 2022 at 10:12: PM
via After rumors of stalled buyout talks between Merck and Seagen, perhaps a new Tukysa indication could reignite interest.

The FDA has granted Tukysa a priority review in combination with Genentech’s Herceptin for second-line HER2-positive metastatic colorectal cancer, the company revealed on Monday.

article source
 




Top Bottom
Back
Quote